Viralytics secures key EU patent
Viralytics Limited announced that the company has been granted a European patent covering the company’s core technology. The Company had announced in May 2008 that a “Notice of Allowance” had been received and that subject to the completion of a number of administrative matters a patent was expected to be granted later in the year. The granted European patent provides Viralytics with exclusive use of Coxsackie A group viruses (including the Company’s lead product CAVATAKTM) for the treatment of all cancers expressing the ICAM-1 molecule until 2020.
Professor Darren Shafren, Chief Scientist for Viralytics and inventor of the technology said, “The patent is similar to the patent granted in the United States of America in April 2008 covering the company’s core technology. Together, these patents give the company a strong intellectual property foundation for potential out-licensing and commercialization of our products and technology.”
Other news from the department research and development
